Pramipexole


Non-ergot D2/D3-preferring dopamine agonist

A non-ergot benzothiazole D3-preferring dopamine receptor agonist; first-line for Parkinson disease and restless legs syndrome.

Abstract

Pramipexole ((6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; CAS 104632-26-0; molecular formula C10H17N3S; molecular weight 211.32) is a non-ergot benzothiazole dopamine receptor agonist developed at Boehringer Ingelheim and approved by the FDA in 1997 under the trade name Mirapex. The compound is D3-preferring (D3 Ki approximately 0.5 nM, D2 Ki approximately 4 nM, ratio approximately 8) with minimal activity at non-dopaminergic receptors, distinguishing it from ergoline agonists by absence of the rare cardiac valvulopathy and serosal fibrosis associated with the ergot agonists. Plasma half-life is 8 to 12 hours; metabolism is minimal (90 percent renal excretion unchanged). Approved for Parkinson disease, restless legs syndrome. The dopaminergic activity produces a recognized risk of impulse control disorders (pathological gambling, hypersexuality) in approximately 14 percent of long-term users.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph